


1. (Amended) A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:




wherein A represents oxygen, sulfur or a group represented by the formula  $>NR^3$  (wherein  $R^3$  represents hydrogen atom or a lower alkyl group);  $R^1$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5-6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower  $C_{3-8}$  cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is  $-CO-N(R_a)R_b$ , wherein  $R_a$  and  $R_b$  are hydrogen and  $C_{1-6}$  alkyl groups;  $R^2$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5-6

*Sub*  
*04*

membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents hydrogen atom, hydroxyl group, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and when A is a sulfur atom, R<sup>1</sup> is an aryl which may have a substituent, a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms, an alkyl which may have a substituent, a heteroarylalkyl which may have a substituent, an arylalkenyl which may have a substituent, a heteroarylalkenyl which may have a substituent,


a piperidyl which may have a substituent,  
 a piperadiny1 which may have a substituent,  
 a morpholinyl which may have a substituent,  
 a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,  
 tetrahydrofuranyl,  
 adamantyl or  
 an optionally substituted amide, that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub>  
 and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and  
 provided that the compounds represented by the following  
 formula (II):



(wherein R<sup>11</sup> and R<sup>12</sup> are the same as or different from each other  
 and each represents hydrogen atom, fluorine, chlorine, bromine,  
 iodine, a C1-C2 fluoroalkyl group, a C1-C2 chloroalkyl group, a  
 C1-C2 bromoalkyl group, a C1-C6 alkyl group, a C3-C6 cycloalkyl  
 group, a C7-C9 aralkyl group, phenyl group, a C1-C6 alkoxy  
 group, a C1-C6 alkylthio group, a C1-C6 alkylsulfinyl group, a  
 C7-C9 aralkoxy group, phenoxy group, phenylthio group,  
 phenylsulfonyl group, an alkali metal carboxylate C2-C5  
 alkoxycarbonyl group or a group represented by the formula -

~~C/1  
 Sub  
 DC1  
 N(R<sup>15</sup>)R<sup>16</sup> (wherein R<sup>15</sup> and R<sup>16</sup> are the same as or different from each other and each represents hydrogen atom or a C1-C2 alkyl group); and R<sup>13</sup> and R<sup>14</sup> are the same as or different from each other and each represents a C<sub>1-4</sub> alkylsulfonyl group, nitro group, a group represented by the formula -OCH<sub>n</sub>X<sub>3-n</sub> (wherein X represents fluorine, chlorine, bromine or iodine; and n is an integer of 1 to 3) or the same groups as defined above for R<sup>11</sup> and R<sup>12</sup>) are excluded.~~

~~C/1  
 Sub  
 DC4  
 7. (Amended) The compound according to claim 1, wherein R<sup>4</sup> and R<sup>5</sup> are hydrogen and which is represented by the following formula (III):~~



~~(wherein A, R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined in claim 1), a pharmacologically acceptable salt thereof or hydrates thereof.~~

~~8. (Amended) The compound according to claim 7, a pharmacologically acceptable salt thereof or hydrates thereof, wherein R<sup>1</sup> is an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an~~

CP  
Sub  
D4

optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, a morpholinyl group, a lower C<sub>3-8</sub> cycloalkyl group, an optionally substituted amino group or an optically substituted amide group that is CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and R<sup>2</sup> is an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, a lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an optionally substituted piperidyl group or an adamantyl group.

9. (Amended) The compound according to claim 7 or 8, a pharmacologically acceptable salt thereof or hydrates thereof, wherein the substituent groups on R<sup>1</sup> and R<sup>2</sup> are hydrogen atom, halogen atom, hydroxyl group, lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkoxy group, lower thioalkoxy group, hydroxy lower thioalkoxy group, arylthio group, heteroaryl thio group, heteroaryl(hydroxy)alkyl group, halogenated lower alkyl group, hydroxy lower alkyl group, dihydroxy lower alkyl group, halogenated (hydroxy) lower alkyl

group, hydroxyalkenyl group, hydroxyalkynyl group, hydroxy lower cycloalkenyl group, lower alkoxy(hydroxy)alkyl group, lower alkoxy(hydroxy)alkoxy group, lower alkoxy alkyl group, lower alkoxy alkoxy group, lower thioalkoxy alkoxy group, lower alkyl sulfonyl alkoxy group, hydroxy lower alkoxy group, dihydroxy lower alkoxy group, hydroxy lower alkyl alkoxy group, hydroxy imino lower alkyl group, lower cycloalkyl(hydroxy)alkyl group, aralkyl group, hydroxyaralkyl group, cyano group, cyano lower alkyl group, amide group that is  $-CO-N(R_a)R_b$ , wherein  $R_a$  and  $R_b$  are hydrogen or  $C_{1-6}$  alkyl group, N-lower alkyl amide group, N-lower cycloalkyl amide group, N,N-di-lower alkyl amide group, N-hydroxy lower alkyl amide group, N-hydroxy lower alkyl-N-lower alkyl amide group, N-aryl amide group, cyclic aminocarbonyl group, carbamoyl group, N-lower alkyl carbamoyl group, N,N-di-lower alkyl carbamoyl group, aminosulfonyl group, cyclic aminosulfonyl group, N-lower alkyl aminosulfonyl group, N-lower cycloalkyl aminosulfonyl group, N,N-di-lower alkyl aminosulfonyl group, N-hydroxy lower alkyl aminosulfonyl group, N-lower alkoxy alkyl aminosulfonyl group, N-halogenated lower alkyl sulfonyl group, pyrrolidinyl sulfonyl group, lower alkyl sulfonyl amino alkyl group, N-lower alkyl aminosulfonyl alkyl group, N,N-di-lower alkyl aminosulfonyl alkyl group, lower acyl group, lower acyl alkyl group, lower cycloalkyl(hydroxy)methyl group, tetrahydropyranyl group, hydroxytetrahydropyranyl group, hydroxy


lower alkyl tetrahydropyranyl group, lower acyl amino alkyl group, (thiazole-2-yl)hydroxymethyl group, di(thiazole-2-yl)hydroxymethyl group, lower alkyl sulfonyl group, lower alkoxy alkyl sulfonyl group, hydroxy lower alkyl sulfonyl group, lower alkyl sulfonyl alkyl group, N-lower alkyl amide alkyl group, aryl group, aralkyl group, heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, heteroaryl lower alkyl group, heteroaryl lower alkoxy group, heteroaryl sulfonyl group, 4-morpholinyl sulfonyl group, 4-oxythiomorpholinyl sulfonyl group, 4-dioxythiomorpholinyl sulfonyl group, 4-morpholinyl sulfonyl group, hydroxy lower cycloalkyl group, hydroxy lower cycloalkyloxy group, hydroxy cycloalkenyl group, halogenated hydroxy lower alkyl group, 4-hydroxypiperidyl group, 4-lower alkoxypiperidyl group,  $\omega,\omega$ -lower alkylene dioxyalkyl group,  $\omega,\omega$ -lower alkylene dioxy alkoxy group, lower cycloalkyl hydroxy methyl group, aryloxy group, aryl aminosulfonyl group, amino group, lower alkyl amino group, di-lower alkyl amino group, hydroxy lower alkyl amino group, lower acyl amino group, hydroxy lower acyl amino group, lower alkyl sulfonyl amino group, pyridyl lower alkoxy group, lower alkyl pyridyl alkoxy group, lower alkoxy hydroxy alkoxy group, lower thioalkoxy alkoxy group, lower alkyl sulfonyl alkoxy group, N-lower alkyl carbamoyl group, N,N-di-lower alkyl carbamoyl group, N-hydroxy

Q2  
Sub  
D4

lower alkyl carbamoyl group, N-hydroxy lower alkyl-N-lower alkyl carbamoyl group, halogenated lower alkoxy group, cyano lower alkoxy group, hydroxy lower cycloalkoxy group, trifluoromethyl group, trifluoromethoxy group, amino lower alkoxy group, N-lower alkyl aminoalkoxy group, N,N-di-lower alkyl aminoalkoxy group, lower acyl alkoxy group, lower acyl aminoalkoxy group, (1,3-dioxolanyl) lower alkyl group, (1,3-dioxolanyl) lower alkoxy group, amide lower alkoxy group, 4-(hydroxy alkyl)tetrahydropyran-4-yl group, 2,3-dihydrobenzofuranyl group, 2-hydroxy-2-alkyl-2,3-dihydrobenzofuranyl group, indanonyl group, hydroxyindanyl group, imidazolyl lower alkoxy group, succimide group or 2-oxazolidone-3-yl group, optionally substituted benzoyloxy lower alkyl group, optionally substituted amino lower alkyl group, optionally substituted amino lower alkoxy group, optionally substituted aralkyloxy group, optionally substituted heteroaryl alkoxy group, optionally substituted morpholinyl lower alkoxy group, optionally substituted piperidyl lower alkoxy group, optionally substituted piperazinyl lower alkoxy group or optionally substituted pyrrolidinyl lower alkoxy group.


10. (Amended) The compound according to claim 7, represented by the following formula (IV):





(wherein R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined in claim 7),  
a pharmacologically acceptable salt thereof or hydrates thereof.

13. (Amended) A pharmaceutical composition comprising a  
pharmacologically acceptable amount of the compound represented  
by the following formula (I), a pharmaceutically acceptable salt  
thereof or hydrates thereof, and pharmacologically acceptable  
carriers:




wherein A represents oxygen, sulfur or a group represented  
by the formula >NR<sup>3</sup> (wherein R<sup>3</sup> represents hydrogen atom or a  
lower alkyl group); R<sup>1</sup> and R<sup>2</sup> are the same as or different from  
each other and each represents an optionally substituted aryl  
group, an optionally substituted heteroaryl group that is formed  
from one or two 5 or 6 membered rings that may contain from 1 to  
4 heteroatoms, an optionally substituted aralkyl group, an  
optionally substituted heteroaryl alkyl group, an optionally  
substituted aryl alkenyl group, an optionally substituted

CB  
Sub  
114

heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents hydrogen atom, hydroxyl group, halogen atom, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and when A is a sulfur atom, R<sup>1</sup> is an aryl which may have a substituent, a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms, an aralkyl which may have a substituent, a heteroarylalkyl which may have a substituent an arylalkenyl which may have a substituent, a heteroarylalkenyl which may have a substituent, a piperidyl which may have a substituent, a piperadinyll which may have a substituent,

*CB*  
*Sub*  
*04*  
a morpholinyl which may have a substituent,  
a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,  
tetrahydrofuranyl,  
adamantyl or  
an optionally substituted amide, that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub>  
and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group.

*C4*  
15. (Amended) A pharmaceutical preparation comprising the  
compound represented by the following formula (I), a  
pharmaceutically acceptable salt thereof or hydrates thereof:



wherein A represents oxygen, sulfur or a group represented  
by the formula >NR<sup>3</sup> (wherein R<sup>3</sup> represents hydrogen atom or a  
lower alkyl group); R<sup>1</sup> and R<sup>2</sup> are the same as or different from  
each other and each represents an optionally substituted aryl  
group, an optionally substituted heteroaryl group that is formed  
from one or two 5-6 membered rings that may contain from 1 to 4  
heteroatoms, an optionally substituted aralkyl group, an  
optionally substituted heteroaryl alkyl group, an optionally  
substituted aryl alkenyl group, an optionally substituted

CH  
Sub  
nu  
~~heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower C<sub>3-8</sub> cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub> and R<sub>b</sub> are hydrogen or C<sub>1-6</sub> alkyl group; and R<sup>4</sup> and R<sup>5</sup> are the same as or different from each other and each represents hydrogen atom, hydroxyl group, a halogen atom, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms provided that A is an oxygen atom, when R<sup>1</sup> and R<sup>2</sup> are both phenyl; and when A is a sulfur atom, R<sup>1</sup> is an aryl which may have a substituent, a heteroaryl which may have a substituent that is formed from one or two 5-6 membered rings that may contain 1-4 heteroatoms, an aralkyl which may have a substituent, a heteroarylalkyl which may have a substituent, an arylalkenyl which may have a substituent, a heteroarylalkenyl which may have a substituent, a piperidyl which may have a substituent, a piperadinyl which may have a substituent,~~

Q4  
Sub  
D4  
a morpholinyl which may have a substituent,  
a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,  
tetrahydrofuranyl,  
adamantyl or  
an optionally substituted amide, that is -CO-N(Ra)Rb, wherein Ra  
and Rb are hydrogen and C<sub>1-6</sub> alkyl group.


C3  
Sub  
D4  
24. (Amended) A method of treating and ameliorating nerve  
degeneration diseases, which comprises administering a  
pharmacologically effective amount of the pharmaceutical  
preparation according to claim 15 or 16 to a patient.

25. (Amended) A method of treating and ameliorating  
demyelinating nerve diseases, which comprises administering a  
pharmacologically effective amount of the pharmaceutical  
preparation according to claim 15 or 16 to a patient.

26. (Amended) A method of treating and ameliorating acute  
nerve degeneration after cerebral ischemia, traumas in the head  
and spinal injuries, Alzheimer's disease, Parkinson's disease,  
amyotrophic lateral sclerosis, Huntington's chorea, epilepsy,  
pain, multiple sclerosis, encephalomyelitis, Guillain Barre  
syndrome, Marchiafava Bignami disease, Devic disease, Balo  
disease, HIV or HTLV myelopathy or leukoencephalopathy, which

Sub  
p4  
25  
comprises administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 15 or 16 to a patient.


06  
Claim 32. A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:



wherein A represents oxygen, sulfur or a group represented by the formula  $>NR^3$  (wherein  $R^3$  represents hydrogen atom or a lower alkyl group);  $R^1$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group, an optionally substituted heteroaryl alkyl group, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower  $C_{3-8}$  cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl

group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is  $-\text{CO}-\text{N}(\text{R}_a)\text{R}_b$  wherein  $\text{R}_a$  and  $\text{R}_b$  are hydrogen and  $\text{C}_{1-6}$  alkyl group;  $\text{R}^2$  represents an optionally substituted aryl group, an optionally substituted heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, an optionally substituted aralkyl group wherein it is not benzyl, an optionally substituted heteroarylalkyl group wherein it is not pyrimidinyl alkyl, an optionally substituted aryl alkenyl group, an optionally substituted heteroaryl alkenyl group, an optionally substituted piperidyl group, an optionally substituted piperazinyl group, a morpholinyl group, an optionally substituted lower  $\text{C}_{3-8}$  cycloalkyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, an adamantyl group, an optionally substituted amino group or an optionally substituted amide group that is  $-\text{CO}-\text{N}(\text{R}_a)\text{R}_b$ , wherein  $\text{R}_a$  and  $\text{R}_b$  are hydrogen and  $\text{C}_{1-6}$  alkyl group; and  $\text{R}^4$  and  $\text{R}^5$  are the same as or different from each other and each represents hydrogen atom, hydroxyl group, nitrile group, nitro group, a lower alkyl group, an aryl group or a heteroaryl group that is formed from one or two 5 or 6 membered rings that may contain from 1 to 4 heteroatoms, provided that A is an oxygen atom, when  $\text{R}^1$  and  $\text{R}^2$  are both phenyl; and

when A is a sulfur atom, R<sup>1</sup> is  
 an aryl which may have a substituent,  
 a heteroaryl which may have a substituent that is formed from  
 one or two 5-6 membered rings that may contain 1-4 heteroatoms,  
 an aralkyl which may have a substituent,  
 a heteroarylalkyl which may have a substituent,  
 an arylalkenyl which may have a substituent,  
 a heteroarylalkenyl which may have a substituent,  
 a piperidyl which may have a substituent,  
 a piperadinyll which may have a substituent,  
 a morpholinyl which may have a substituent,  
 a lower C<sub>3-8</sub> cycloalkyl which may have a substituent,  
 tetrahydrofuranyl,  
 adamantyl or  
 an optionally substituted amide, that is -CO-N(R<sub>a</sub>)R<sub>b</sub>, wherein R<sub>a</sub>  
 and R<sub>b</sub> are hydrogen and C<sub>1-6</sub> alkyl group; and  
 provided that the compounds represented by the following  
 formula (II):





~~(wherein,  $R^{11}$  and  $R^{12}$  are the same as or different from each other and each represents hydrogen atom, fluorine, chlorine, bromine, iodine, a C1-C2 fluoroalkyl group, a C1-C2 chloroalkyl group, a C1-C2 bromoalkyl group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C7-C9 aralkyl group, phenyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group, a C1-C6 alkylsulfinyl group, a C7-C9 aralkoxy group, phenoxy group, phenylthio group, phenylsulfonyl group, an alkali metal carboxylate C2-C5 alkoxy carbonyl group or a group represented by the formula  $-N(R^{15})R^{16}$  (wherein  $R^{15}$  and  $R^{16}$  are the same as or different from each other and each represents hydrogen atom or a C1-C2 alkyl group); and  $R^{13}$  and  $R^{14}$  are the same as or different from each other and each represents a C<sub>1-4</sub> alkylsulfonyl group, nitro group, a group represented by the formula  $-OCH_nX_{3-n}$  (wherein X represents fluorine, chlorine, bromine or iodine; and n is an integer of 1 to 3) or the same groups as defined above for  $R^{11}$  and  $R^{12}$ ) are excluded.~~

Please add the following claims:

~~--33. (new) A method of preventing a disease selected from the group consisting of epilepsy, multiple sclerosis, Huntington's chorea, Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis comprising administering an effective amount of~~